Nexia Biotechnologies of Quebec, Canada, has unveiled its plans todevelop a herd of transgenic goats which will produce complex proteins, including human growth hormone, in their milk. Nexia is partnering the project with Genzyme Transgenics of the USA.
Nexia has developed its own breed of goat, called BELE (breed early, lactate early), to speed up the production process. They produce milk at 12 months rather than at 18 months, according to Nexia. The two companies were reluctant to say too much about the other proteins they are seeking to manufacture in this manner, but hinted that an early target will be a hematopoietic factor.
Four-year-old Nexia has received about C$8.5 million ($6 million) in venture capital funding, and around C$2.5 million from Genzyme. The company hopes to list on a stock market in the next year or so.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze